LAVA Therapeutics Announces Annual Meeting of Shareholders

Rhea-AI Summary

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that its Annual General Meeting of Shareholders is set for June 15, 2022, at 7:30 a.m. CEST in Amsterdam, Netherlands. Important documents regarding the meeting, including the notice and agenda, are accessible through LAVA’s investor website and the SEC. LAVA Therapeutics is focused on immuno-oncology, utilizing its Gammabody™ technology to develop bispecific gamma delta T cell engagers targeting solid and hematologic cancers. The lead candidate, LAVA-051, is in a Phase 1/2a clinical study for multiple myeloma and other malignancies.

Positive

• The Annual General Meeting will provide shareholders with updates on company progress.
• LAVA-051 is actively enrolling patients in a Phase 1/2a clinical study, indicating ongoing research and development efforts.

Negative

• None.

UTRECHT, The Netherlands and PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Annual General Meeting of Shareholders will take place on Wednesday, June 15, 2022, at 7:30 a.m. CEST, at Beethovenstraat 400, 1082 PR, Amsterdam, the Netherlands.

All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are available in the “Investors” section of LAVA’s website (www.lavatherapeutics.com) under “Annual Meeting.” The documents will also be made available on the SEC’s website (www.sec.gov). Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting.

About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.

CONTACTS
Investor Relations
ir@lavatherapeutics.com

Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com

FAQ

When is the Annual General Meeting of LAVA Therapeutics scheduled?

The Annual General Meeting of LAVA Therapeutics is scheduled for June 15, 2022, at 7:30 a.m. CEST.

Where is the LAVA Therapeutics Annual General Meeting taking place?

The meeting will take place at Beethovenstraat 400, 1082 PR, Amsterdam, the Netherlands.

What are LAVA Therapeutics' lead clinical trials?

LAVA-051 is in a Phase 1/2a clinical study for multiple myeloma and other cancers, while LAVA-1207 is being evaluated in patients with metastatic castration-resistant prostate cancer.

Where can shareholders find documents related to the Annual General Meeting?

Documents regarding the meeting can be found in the 'Investors' section of LAVA’s website and on the SEC's website.